Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | August 20, 2018 | August 22, 2018 |
| DEXCOM INCDXCM · Entity 3114 | Director | May 28, 2026 | June 01, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | June 08, 2023 | June 09, 2023 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director · President & CEO | October 06, 2026 | October 07, 2026 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, Chief Financial Officer | November 20, 2018 | November 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.08 · Expires 2028-08-20 | Direct | 25,000 |
Reported balance
After 2018-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-20 · Grant · Acquired 25,000 · Balance 25,000 F1: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period.
DEXCOM INC
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,486 |
Reported balance
After 2026-05-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 5,605 · Balance 12,486 F1: The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2: Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
F2: Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028.
Gossamer Bio, Inc.
Report date June 08, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2033-06-07 | Direct | 35,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 35,000 · Balance 35,000 F1: Award made pursuant to Non-Employee Director Compensation Program. F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award made pursuant to Non-Employee Director Compensation Program.
F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Jazz Pharmaceuticals plc
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 141,394 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 2,000 · Balance 141,394 F1: This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Theravance Biopharma, Inc.
Report date November 20, 2018 · Filed November 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 157,657 |
Reported balance
After 2018-11-20 transaction · row 1
1 source rowRow 1 · 2018-11-20 · Tax withholding · Disposed 6,697 · Balance 157,657 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2018 Filed Aug 16, 2018 23:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,204 | $27.74 | $61,135.87 |
DisclosureSEC source: 0001179110-18-010637 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,588 F1 · price: This transaction was executed in multiple trades at prices from $27.515 to $28.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2018 Filed May 22, 2018 23:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 21,230 | $24.31 | $516,101.30 |
DisclosureSEC source: 0001179110-18-007370 · edgar.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,792 Read SEC document |
| May 18, 2018 Filed May 22, 2018 23:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 10,000 | $24.29 | $242,877.00 |
DisclosureSEC source: 0001179110-18-007370 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,022 F1 · price: This transaction was executed in multiple trades at prices from $24.14 to $24.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006934 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,022 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. F2 · balance_after: Includes 865 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 01:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 9,000 | $15.53 | $139,801.50 |
DisclosureSEC source: 0000899243-18-006756 · doc4.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Represents the weighted average purchase price for the entire number of shares purchased. The actual purchase prices range from $15.5334 to $15.5399 per share. Detailed information on the exact number of shares purchased at each purchase price can be obtained from the issuer upon request. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 01:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 1,000 | $15.30 | $15,300.00 |
DisclosureSEC source: 0000899243-18-006756 · doc4.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,387 | $29.09 | $156,707.83 |
DisclosureSEC source: 0001179110-18-002606 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,407 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002120 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,794 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 21:35 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,753 | $28.58 | $193,000.74 |
DisclosureSEC source: 0001179110-17-014561 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,794 Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 22:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,752 | $27.40 | $185,004.80 |
DisclosureSEC source: 0001179110-17-011746 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,547 Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $12.13 | $0.00 |
DisclosureSEC source: 0000899243-17-014589 · doc4.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 24, 2017 over one-year period. Read SEC document |
| May 20, 2017 Filed May 23, 2017 23:58 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,753 | $36.83 | $248,712.99 |
DisclosureSEC source: 0001179110-17-007876 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,299 F1 · balance_after: Includes 1,702 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2017. Read SEC document |
| February 20, 2017 Filed Feb 23, 2017 00:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,211 | $33.78 | $344,927.58 |
DisclosureSEC source: 0001179110-17-002988 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,350 Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001997 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,561 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 23:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,628 | $31.96 | $147,910.88 |
DisclosureSEC source: 0001179110-16-031975 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,561 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.